APYX (Apyx Medical) Change In Payables And Accrued Expense: $-0.42 Mil (TTM As of Mar. 2026)

Apyx Medical APYX +6.79% 65 Change In Payables And Accrued Expense is $-0.42 Mil as of Mar. 2026. GuruFocus rates APYX with a GF Score™ of 65/100 and a GF Value™ of $2.17 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Apyx Medical's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2026 was $-2.17 Mil. It means Apyx Medical's Accounts Payable & Accrued Expense declined by $2.17 Mil from Dec. 2025 to Mar. 2026 .

Apyx Medical's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2025 was $0.56 Mil. It means Apyx Medical's Accounts Payable & Accrued Expense increased by $0.56 Mil from Dec. 2024 to Dec. 2025 .

Apyx Medical Change In Payables And Accrued Expense Related Terms

Apyx Medical Change In Payables And Accrued Expense Historical Data

* Premium members only.

The historical data trend for Apyx Medical's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apyx Medical Change In Payables And Accrued Expense Chart

Apyx Medical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

4.55

-1.14

0.30

-2.33

0.56

Apyx Medical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-1.19	0.95	0.41	0.40	-2.17

65GF Score

Apyx Medical Corp APYX

Change In Payables And Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Apyx Medical Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.42 Mil.

Frequently Asked Questions Learn more about Change In Payables And Accrued Expense →

What does a Change In Payables And Accrued Expense of $-0.42 Mil mean?

Apyx Medical (APYX) has a Change In Payables And Accrued Expense of $-0.42 Mil as of Mar. 2026. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Apyx Medical and its competitors.

Is Apyx Medical's Change In Payables And Accrued Expense too high?

Apyx Medical's current Change In Payables And Accrued Expense is $-0.42 Mil. Overall, Apyx Medical has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Apyx Medical's Change In Payables And Accrued Expense compare to OWLT and INGN?

Apyx Medical's Change In Payables And Accrued Expense of $-0.42 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Payables And Accrued Expense for a Medical Devices & Instruments company?

A good Change In Payables And Accrued Expense depends on the Medical Devices & Instruments industry context. However, Change In Payables And Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Payables And Accrued Expense mean?

A high Change In Payables And Accrued Expense can signal that a stock is expensive relative to its fundamentals. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Apyx Medical and its competitors. Apyx Medical's current Change In Payables And Accrued Expense is $-0.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Apyx Medical stock overvalued right now?

Based on GuruFocus' analysis, Apyx Medical (APYX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.17, compared to a current price of $4.33 — trading 99.3% above its estimated fair value. The current Change In Payables And Accrued Expense is $-0.42 Mil. Apyx Medical's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Payables And Accrued Expense calculated?

Change In Payables And Accrued Expense is calculated from a company's financial statements. For Apyx Medical (APYX), the current Change In Payables And Accrued Expense is $-0.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apyx Medical (APYX) Overvalued in 2026?

Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued. The current stock price of $4.33 is trading 99.3% above its estimated GF Value™ of $2.17. GuruFocus considers Apyx Medical to be Significantly Overvalued.

Key valuation signals for APYX:

Change In Payables And Accrued Expense: $-0.42 Mil
GF Value™: $2.17 vs. price of $4.33 (99.3% above fair value)
GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the APYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apyx Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OWLT INGN TANAF HYPR INFU CVRX QTRX SNWV LUCD NNOX ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges BOV:Germany

Address 5115 Ulmerton Road, Clearwater, FL, USA, 33760

Website https://apyxmedical.com

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.

65GF Score

Get the complete analysis for APYX

Change In Payables And Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.33

Price

$2.17

GF Value

View APYX Analysis

See Change In Payables And Accrued Expense data for all stocks →